Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2000248 Feb 2020

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2000003 Jan 2020

INTENDED FOR UK HEALTHCARE PROFESSIONALS
Fostair® logo (beclometasone/formoterol) Extrafine formulation 100/6 & 200/6
Background

Prescribing Fostair in COPD

trimbow_subheader-mobile

Fostair gives you freedom to choose the appropriate device for your patient without having to consider an increase in price.

Fostair pMDI 100/6 and Fostair NEXThaler 100/6 are indicated in the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.1,2 Both devices deliver 100 micrograms of beclometasone dipropionate and 6 micrograms of formoterol fumarate per inhalation.1,2

How to prescribe Fostair

Use Fostair pMDI 100/6:

Two puffs in the morning Two puffs in the evening

Use Fostair NEXThaler 100/6:

Two puffs in the morning Two puffs in the evening

Fostair NEXThaler: optimised for drug delivery and patient reassurance[[3-5]]

An easy device to operate1,3,

NEXThaler device opening - Open - NEXThaler device being used - Inhale - NEXThaler device being closed - Close

Full dose delivery4,6–10

Patients receive a full dose with consistent lung deposition, above a flow rate of 35 L/min4,6–10

Designed for patient reassurance1,3,4,7–10

Graphic - Ear - Click

Fostair NEXThaler’s audible ‘click’ reassures patients that the dose has been taken1,3

35 L/min

Fostair NEXThaler’s dose counter only counts successful individual inhalations, so each dose registered equals a dose taken1,3

With Fostair NEXThaler you know that no dose is wasted6

  • Fostair NEXThaler’s unique dose protector means the dose is only released on inhalation above a flow rate of 35 L/min, so you can be sure that all doses have been taken and none wasted6
  • Fostair NEXThaler’s dose counter only counts successful individual inhalations, so each dose registered equals a dose taken1

For patients currently using Fostair plus a long-acting muscarinic antagonist (LAMA) – click here for Trimbow® (beclometasone/formoterol/glycopyrronium) information11

For additional information to share with your patients who have been prescribed Fostair NEXThaler or Fostair pMDI please visit our Fostair NEXThaler patient and carer site or Fostair pMDI patient and carer site.

Click here for Fostair® (beclometasone/formoterol) Prescribing Information.

Click here for Trimbow® (beclometasone/formoterol/glycopyrronium) Prescribing Information.

COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 second; LAMA: long-acting muscarinic antagonist; pMDI: pressurised metered dose inhaler.

References:
1. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
2. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
3. Voshaar T, et al. J Aerosol Med Pulm Drug Deliv. 2014; 27(5): 363–370.
4. De Backer W, et al. J Aerosol Med Pulm Drug Deliv. 2010; 23(3): 137–148.
5. Farkas A, et al. Int J Pharm. 2017; 533(1): 225–235.
6. Corradi M, et al. Expert Opin Drug Deliv. 2014; 11(9): 1497–1506.
7. Virchow JC, et al. J Aerosol Med Pulm Drug Deliv. 2018; 31(5): 269–280.
8. Buttini F, et al. J Aerosol Med Pulm Drug Deliv. 2016; 29(2): 167–178.
9. Pasquali I, Brambilla G. RDD Europe 2013 (Berlin, Germany; May 21–24).
10. Mariotti F, et al. Eur Resp J. 2011; 38: 830.
11. Trimbow Summary of Product Characteristics. Chiesi Limited.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Ltd on 0800 0092329 (UK), 1800 817459 (IE) PV.UK@Chiesi.com.